Media
Neumentum Announces Two Poster Presentations for Novel Non-opioid, Non-NSAID Analgesic Drug Candidate at PAINWeek 2020
MORRISTOWN, NJ, September 3, 2020 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – will present two posters with data on NTM-006, a new chemical entity (NCE) non-opioid, non-NSAID analgesic candidate that...
Neumentum Provides Corporate Update on Company’s Pipeline of Non-opioid Analgesic Programs
Neumentum Provides Corporate Update on Company’s Pipeline of Non-opioid Analgesic Programs October 2020 Type C meeting planned with the FDA for NTM-006, an oral new chemical entity with a novel mechanism of action targeting neuropathic pain Based on recent FDA...
Neumentum, Inc. Chief Executive Officer Scott Shively to Present at BIO Digital Conference
PALO ALTO, Calif., June 5, 2020 – Neumentum, Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer, has posted a presentation for digital viewing for the BIO...
Neumentum Enters into Global Licensing Agreement for a Novel Class of Investigational Pain Treatments
Agreement significantly expands Neumentum’s pipeline of investigational pain therapies aimed at addressing the growing need for innovative analgesics PALO ALTO, Calif., October 10, 2019 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain...
Neumentum Presents Data on Lead Product Candidate NTM-001 at PAINWeek 2019
Neumentum's poster presentations #39, #40, #41 and #42 from PAINWeek are now available to view. - Results Support What Has the Potential To Be the First-Ever Non-Steroidal Anti-Inflammatory (NSAID) Approved for Continuous Infusion - Results Confirm Potential to...
Neumentum Phase I Study Confirms Its Non-Opioid in Development for Moderately Severe Acute Pain, NTM-001, Performs in Healthy Adults as Predicted
– The Phase I Clinical Study of a Continuously Infused NSAID, NTM-001, Provided Steady Plasma Levels of Ketorolac Over 24 Hours, With No Unexpected Adverse Effects – Alcohol-Free, Stable Formulation of Ketorolac in a Pre-Mixed Bag for Continuous Infusion Has the...
Neumentum Announces Dosing of Patients in Phase I Study Evaluating Its Lead Product Candidate, NTM-001, a Non-Opioid in Development for the Management of Moderately Severe Acute Pain
- Potential to be the First Continuously Infused NSAID to be Successfully Developed for Acute Post-Operative Pain in the US - NTM-001 is an Investigational, Alcohol-Free, Stable Formulation of Ketorolac in a Pre-Mixed Bag for Continuous Infusion with the Potential to...
Neumentum Announces Dosing of Patients in Phase I Study
Neumentum Announces Dosing of Patients in Phase I Study Evaluating Its Lead Product Candidate, NTM-001, a Non-Opioid in Development for the Management of Moderately Severe Acute Pain.
Neumentum Confirms Type B Meeting with FDA and Announces New Chief Medical and Scientific Officers
-- May 8 Type B meeting confirmed to discuss the clinical development program for lead product candidate NTM-001, which has potential to treat moderately severe acute postoperative pain that requires analgesia at the opioid level, reducing the need for opioids in the...
Neumentum Raises $6 Million in Series A Funding to Develop Non-opioid Pain Products and Requests Type B Meeting with FDA
-- Led by proven executive team, Neumentum is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company -- -- Type B meeting requested to discuss phase 3 program for lead product candidate NTM-001, which has the potential to...